Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 5, 2010, Pages 1180-1193

  Kato, S ^a   Smalley, S ^a   Sadarangani, A ^a   Chen Lin, K ^a   Oliva, B ^a   Branes J ^a   Carvajal, J ^a   Gejman, R ^a   Owen, G I ^a   Cuello, Mauricio ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Apoptosis; Gynaecological cancers; Statins; Therapy

Indexed keywords

FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID PHOSPHATE; LIPID; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; SESQUITERPENE; SIMVASTATIN; WATER;

ARTICLE; CELL DEATH; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; ENZYMOLOGY; EPITHELIUM; FEMALE; FEMALE GENITAL TRACT TUMOR; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; OVARY TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UTERINE CERVIX TUMOR; DRUG EFFECTS;

CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EPITHELIUM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENITAL NEOPLASMS, FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; LOVASTATIN; MEVALONIC ACID; OVARIAN NEOPLASMS; POLYISOPRENYL PHOSPHATES; PRAVASTATIN; SESQUITERPENES; SIGNAL TRANSDUCTION; SIMVASTATIN; UTERINE CERVICAL NEOPLASMS; WATER;

EID: 77954696092     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00771.x     Document Type: Article

References (52)

1. Heintz AP, Odicino F, Maisonneuve P. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006, 95:S161-92.
2. Creasman WT, Odicino F, Maisonneuve P. Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006, 95:S105-43.
3. Quinn MA, Benedet JL, Odicino F. Carcinoma of the cervix uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006, 95:S43-103.
4. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008, 14:37-44.
5. Beckman JA, Creager MA. The nonlipid effects of statins on endothelial function. Trends Cardiovasc Med. 2006, 16:156-62.
6. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents. Circulation 2004, 109:II18-26.
7. Forrester JS, Libby P. The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol. 2007, 99:732-8.
8. Arnaud C, Mach F. Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation. Arch Mal Coeur Vaiss. 2005, 98:661-6.
9. Undas A, Celinska-Lowenhoff M, Domagala TB. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost. 2005, 94:193-9.
10. Graaf MR, Beiderbeck AB, Egberts AC. The risk of cancer in users of statins. J Clin Oncol. 2004, 22:2388-94.
11. Sassano A, Platanias LC. Statins in tumor suppression. Cancer Lett. 2008, 260:11-9.
12. Friis S, Poulsen AH, Johnsen SP. Cancer risk among statin users: a population-based cohort study. Int J Cancer. 2005, 114:643-7.
13. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med. 2000, 160:2363-8.
14. Khurana V, Caldito G, Ankem M. Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans. Urology. 2008, 71:118-22.
15. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer. 2008, 44:2122-32.
16. Moorman PG, Hamilton RJ. Statins and cancer risk: what do we know and where do we go from here. Epidemiology. 2007, 18:194-6.
17. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998, 19:26-37.
18. White CM. Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. J Clin Pharmacol. 1999, 39:111-8.
19. Pfefferkorn JA, Song Y, Sun KL. Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors. Bioorg Med Chem Lett. 2007, 17:4538-44.
20. Karp I, Behlouli H, Lelorier J. Statins and cancer risk. Am J Med. 2008, 121:302-9.
21. Cafforio P, Dammacco F, Gernone A. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005, 26:883-91.
22. Katz MS. Therapy insight: potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol. 2005, 2:82-9.
23. Yu O, Boudreau DM, Buist DS. Statin use and female reproductive organ cancer risk in a large population-based setting. Cancer Causes Control 2008
24. Elmore RG, Ioffe Y, Scoles DR. Impact of statin therapy on survival in epithelial ovarian cancer. Gynecol Oncol. 2008, 111:102-5.
25. Han Z, Wyche JH. Lovastatin induces apoptosis in a metastatic ovarian tumour cell line. Cell Death Differ. 1996, 3:223-8.
26. Liu H, Liang SL, Kumar S. Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression. Cancer Chemother Pharmacol. 2009, 63:997-1005.
27. Sadarangani A, Kato S, Espinoza N. TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. Apoptosis. 2007, 12:73-85.
28. Kato S, Sadarangani A, Lange S. The oestrogen metabolite 2-methoxyoestradiol alone or in combination with tumour necrosis factor-related apoptosis-inducing ligand mediates apoptosis in cancerous but not healthy cells of the human endometrium. Endocr Relat Cancer. 2007, 14:351-68.
29. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987, 162:156-9.
30. Kato S, Pinto M, Carvajal A. Tissue factor is regulated by epidermal growth factor in normal and malignant human endometrial epithelial cells. Thromb Haemost. 2005, 94:444-53.
31. Webb JL. Effects of more than one inhibitor. Enzymes and metabolic inhibitors 1963, 487-512. Webb JL. In, editor, First ed, New York, Academic Press, pp
32. Chou TC, Motzer RJ, Tong Y. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst. 1994, 86:1517-24.
33. Notarnicola M, Messa C, Pricci M. Up-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in left-sided human colon cancer. Anticancer Res. 2004, 24:3837-42.
34. Li X, Liu L, Tupper JC. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem. 2002, 277:15309-16.
35. Bustelo XR, Sauzeau V, Berenjeno IM. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays. 2007, 29:356-70.
36. Ukomadu C, Dutta A. p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. J Biol Chem. 2003, 278:43586-94.
37. Fromigue O, Hay E, Modrowski D. RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ. 2006, 13:1845-56.
38. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005, 19:117-25.
39. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006, 112:71-105.
40. Watanabe T, Kusuhara H, Maeda K. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther. 2009, 328:652-62.
41. Kusuhara H, Sugiyama Y. Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release. 2002, 78:43-54.
42. Hector S, Nava ME, Clark K. Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10. Cancer Lett. 2007, 245:195-204.
43. Guijarro C, Blanco-Colio LM, Massy ZA. Lipophilic statins induce apoptosis of human vascular smooth muscle cells. Kidney Int Suppl 1999, 71:S88-91.
44. Turner NA, Midgley L, O'Regan DJ. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol. 2007, 50:458-61.
45. Kubota T, Fujisaki K, Itoh Y. Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors. Biochem Pharmacol. 2004, 67:2175-86.
46. Jin Z, Dicker DT, El-Deiry WS. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle. 2002, 1:82-9.
47. Ghosh-Choudhury N, Mandal CC, Choudhury GG. Statin-induced Ras activation integrates the phosphatidylinositol 3-kinase signal to Akt and MAPK for bone morphogenetic protein-2 expression in osteoblast differentiation. J Biol Chem. 2007, 282:4983-93.
48. Calleros L, Lasa M, Rodriguez-Alvarez FJ. RhoA and p38 MAPK mediate apoptosis induced by cellular cholesterol depletion. Apoptosis. 2006, 11:1161-73.
49. Kofler S, Schlichting C, Jankl S. Dual mode of HMG-CoA reductase inhibition on dendritic cell invasion. Atherosclerosis. 2008, 197:105-10.
50. Horiuchi A, Kikuchi N, Osada R. Overexpression of RhoA enhances peritoneal dissemination: RhoA suppression with Lovastatin may be useful for ovarian cancer. Cancer Sci. 2008, 99:2532-9.
51. Montero J, Morales A, Llacuna L. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res. 2008, 68:5246-56.
52. Holstein SA, Hohl RJ. Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther. 2001, 1:141-9.